Last reviewed · How we verify
Naltrexone pharmacotherapy
At a glance
| Generic name | Naltrexone pharmacotherapy |
|---|---|
| Sponsor | Finnish Institute for Health and Welfare |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients (PHASE1, PHASE2)
- The Whole Health Study: Collaborative Care for OUD and Mental Health Conditions (NA)
- Naltrexone in AUD Reward Drinkers (PHASE4)
- Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) (PHASE2)
- Integrated Digital Intervention for Alcohol Use Disorder (PHASE2, PHASE3)
- Weight Loss Management in Endometrial Cancer Survivors
- Methamphetamine Use Disorder Support in Heart Failure Pilot Study (NA)
- Anti-obesity Pharmacotherapy and Inflammation
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Naltrexone pharmacotherapy CI brief — competitive landscape report
- Naltrexone pharmacotherapy updates RSS · CI watch RSS
- Finnish Institute for Health and Welfare portfolio CI